| Malisa May Lemon, LCSW | |
|
5284 S Commerce Dr Ste C134, Murray, UT 84107-5360 | |
| (801) 266-4643 | |
| Not Available |
| Full Name | Malisa May Lemon |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 5284 S Commerce Dr Ste C134, Murray, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043645351 | NPI | - | NPPES |
| 14495254 | Other | CAQH |
| Entity Name | Tanner Memorial Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447239355 PECOS PAC ID: 4284547985 Enrollment ID: O20031110000132 |
News Archive
The human brain consists of approximately one hundred billion nerve cells. Each of these cells needs to connect to specific other cells during the brain's development in order to form a fully functional organism. Yet how does a nerve cell know where it should grow and which cells to contact? Scientists of the Max Planck Institute of Neurobiology in Martinsried have now shown that growing nerve cells realise when they've reached their target area in the fly brain thanks to the interaction of two genes.
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
A legislative task force has been reviewing ways to prevent violence, improve school safety and study psychiatric commitment laws.
› Verified 8 days ago
| Entity Name | Thrive Counseling Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215181300 PECOS PAC ID: 0749458420 Enrollment ID: O20210915002356 |
News Archive
The human brain consists of approximately one hundred billion nerve cells. Each of these cells needs to connect to specific other cells during the brain's development in order to form a fully functional organism. Yet how does a nerve cell know where it should grow and which cells to contact? Scientists of the Max Planck Institute of Neurobiology in Martinsried have now shown that growing nerve cells realise when they've reached their target area in the fly brain thanks to the interaction of two genes.
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
A legislative task force has been reviewing ways to prevent violence, improve school safety and study psychiatric commitment laws.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Malisa May Lemon, LCSW 5284 S Commerce Dr Ste C134, Murray, UT 84107-5360 Ph: (801) 266-4643 | Malisa May Lemon, LCSW 5284 S Commerce Dr Ste C134, Murray, UT 84107-5360 Ph: (801) 266-4643 |
News Archive
The human brain consists of approximately one hundred billion nerve cells. Each of these cells needs to connect to specific other cells during the brain's development in order to form a fully functional organism. Yet how does a nerve cell know where it should grow and which cells to contact? Scientists of the Max Planck Institute of Neurobiology in Martinsried have now shown that growing nerve cells realise when they've reached their target area in the fly brain thanks to the interaction of two genes.
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
In an effort to create a uniform and accurate method for determining brain death, the American Academy of Neurology has issued an updated guideline that provides doctors with a step-by-step process for determining brain death in adults. The guideline is published in the June 8, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
A legislative task force has been reviewing ways to prevent violence, improve school safety and study psychiatric commitment laws.
› Verified 8 days ago
Mr. James Matthew Upton, LCSW, BCBA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4444 S 700 E Ste 203, Murray, UT 84107 Phone: 801-268-4887 | |
Shane D Adamson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 525 E 4500 S, F-200, Murray, UT 84107 Phone: 801-747-2300 | |
Nancy M Hogarty Baker, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5250 So Commerce Dr, Ste 250, Murray, UT 84107 Phone: 801-261-3500 Fax: 801-261-2111 | |
Sevon Taroian, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 154 E Myrtle Ave Ste 204, Murray, UT 84107 Phone: 801-369-8989 Fax: 801-704-9741 | |
Sloane Rampton, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4848 S Commerce Dr, Murray, UT 84107 Phone: 385-232-3484 | |
Mary Elizabeth Andolsek, LCSW,CT Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5411 S Vine St # 6, Murray, UT 84107 Phone: 801-783-8401 |